Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cobitolimod
- Development stage
- Discontinued
- Lead developer
- Flerie
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical, Rectal
01
Overview
Cobitolimod is a DNA-based synthetic oligonucleotide that acts as an agonist of Toll-like receptor 9 (TLR9). It is designed to modulate the immune response by activating TLR9 in the colonic mucosa. This activation leads to anti-inflammatory effects through suppression of Th17 cells and induction of anti-inflammatory FoxP3-positive regulatory T cells. Cobitolimod has been primarily developed for the treatment of moderate to severe ulcerative colitis and has shown efficacy in clinical trials for patients with left-sided disease who are refractory to conventional therapies. The drug is administered topically via rectal route[4][5][7].
- Brand names
- Kappaproct
- Other names
- cobitolimod sodiumAEL
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on cobitolimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cobitolimod.